Growth in Biologics Market Continues to Drive Injectable Drug Delivery Industry
As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.
Minneapolis, MN (PRWEB) October 17, 2006
As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.
The global market for drug delivery technology is worth in excess of US$25 billion in sales. Given its predicted annual growth of 15 percent, the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. According to Arrowhead Publishers’ new report entitled Injectable Drug Delivery: Market Impact and Industry Trends, injectables currently account for an estimated 15 percent of the global drug delivery market, with the US being the leading individual market.
Despite tough competition from other drug delivery systems, oral in particular, due to its convenient mode of administration – injectable drug delivery systems hold considerable commercial potential, especially in relation to the delivery of biologics as well as mass vaccination requirements. Injectable technology is an essential component of the burgeoning biotechnology industry. No other delivery routes have proven to be as effective at delivering biologics as injectable delivery methods have been.
At present, over 400 genetically engineered drugs are under development as injectables. A growing number of pharmaceutical-biotechnology collaborations are illustrating the importance of the field as a new revenue-generator. Collaborative efforts are often the only way to profitability for smaller drug delivery companies, with pharmaceutical giants – including Pfizer, Roche, Novartis, to name but a few - also benefiting by replenishing their drug pipelines and adding greater value to their existing products.
The development of and the therapeutic advances provided by biotechnology will stimulate research into new methods of drug delivery, and especially that of injectables as they remain the most suitable method of administering proteins and large molecules. At present, over 300 products are under development in the field of biotechnology, with a high percentage of monoclonal antibodies (MAbs) that are difficult to administer by non-invasive systems, but are expected to account for over one-third of total pharmaceutical sales in the coming years. Therefore, the injectable technology, and in particular, needleless therapies, will continue to provide a commercial impetus to pharmaceutical and drug delivery companies.
Injectable Drug Delivery: Market Impact and Industry Trends examines the current trends in the injectables market, with a focus on the main players, key therapeutic areas and products, and the future of the sector.
For more information, visit www. arrowheadpublishers. com, or
1-612-929-5203.
###
